Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction

被引:59
|
作者
Wang, Shuai [1 ,2 ,6 ,7 ]
Zhao, Lijie [1 ,2 ,6 ,7 ]
Shi, Xiao-Jing [1 ,2 ,6 ,7 ]
Ding, Lina [1 ,2 ,6 ,7 ]
Yang, Linlin [8 ]
Wang, Zhi-Zheng [1 ,2 ,6 ,7 ]
Shen, Dandan [1 ,2 ,6 ,7 ]
Tang, Kai [1 ,2 ,6 ,7 ]
Li, Xiao-Jing [1 ,2 ,6 ,7 ]
Mamun, M. A. A. [1 ,2 ,6 ,7 ]
Li, Huiju [1 ,2 ,6 ,7 ]
Yu, Bin [1 ,2 ,6 ,7 ,9 ]
Zheng, Yi-Chao [1 ,2 ,6 ,7 ]
Wang, Shaomeng [1 ,2 ,3 ,4 ,5 ]
Liu, Hong-Min [1 ,2 ,6 ,7 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Inst Drug Discovery & Dev, Zhengzhou 450001, Henan, Peoples R China
[3] Univ Michigan, Dept Internal Med, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pharmacol, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Med Chem, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[6] Coinnovat Ctr Henan Prov New Drug R&D Preclin Saf, Zhengzhou 450001, Henan, Peoples R China
[7] Zhengzhou Univ, Minist Educ China, Key Lab Adv Technol Drug Preparat Technol, Zhengzhou 450001, Henan, Peoples R China
[8] Zhengzhou Univ, Sch Basic Med Sci, Dept Pharmacol, Zhengzhou 450001, Henan, Peoples R China
[9] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划; 中国博士后科学基金;
关键词
CULLIN-RING LIGASES; NEDD8-ACTIVATING ENZYME; E3; LIGASE; DEGRADATION; NEDDYLATION; DISCOVERY; CARCINOMA; UBIQUITINATION; AMPLIFICATION; PROGRESSION;
D O I
10.1021/acs.jmedchem.9b00113
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our in-house library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated.
引用
收藏
页码:2772 / 2797
页数:26
相关论文
共 39 条
  • [31] BBT-401 IS A SELECTIVE PELLINO-1 PROTEIN-PROTEIN INTERACTION INHIBITOR IN CLINICAL DEVELOPMENT TARGETING A FIRST-IN-CLASS DRUG FOR UC TREATMENT
    Lee, Gwanghee
    Lee, YounSook
    Chang, Mikyoung
    Kang, Sang U. K.
    Ryou, Jeong-Hyun
    Lim, Jong-Jin
    Imran, Ali
    Park, Seok-Hee
    Lee, Kwangho
    Lee, Yong-Hee
    GASTROENTEROLOGY, 2019, 156 (03) : S82 - S82
  • [32] Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction
    Schaap, Marjolein
    Hancock, Rowena
    Wilderspin, Andrew
    Wells, Geoff
    PROTEIN SCIENCE, 2013, 22 (12) : 1812 - 1819
  • [33] Correction to "Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors"(vol 67,Pg 3741-3763,2024)
    Otake, Kazuki
    Hara, Yoshinori
    Ubukata, Minoru
    Inoue, Masafumi
    Nagahashi, Noboru
    Motoda, Dai
    Ogawa, Naoki
    Hantani, Yoshiji
    Hantani, Rie
    Adachi, Tsuyoshi
    Nomura, Akihiro
    Yamaguchi, Keishi
    Maekawa, Mariko
    Mamada, Hideaki
    Motomura, Takahisa
    Sato, Motohide
    Harada, Kazuhito
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (17) : 15925 - 15925
  • [34] BBT-401 IS A SELECTIVE PELLINO-1 PROTEIN-PROTEIN INTERACTION INHIBITOR IN CLINICAL DEVELOPMENT TARGETING A FIRST-IN-CLASS DRUG FOR UC TREATMENT.
    Lee, Gwanghee
    Lee, YounSook
    Chang, Mikyoung
    Kang, Sang Uk
    Ryou, Jeong-Hyun
    Lim, Jong-Jin
    Imran, Ali
    Park, Seok-Hee
    Lee, Kwangho
    Lee, Yong-Hee
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S58 - S58
  • [35] Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities
    Nie, Zhe
    Perretta, Carin
    Erickson, Philip
    Margosiak, Stephen
    Lu, Jia
    Averill, April
    Almassy, Robert
    Chua, Shaosong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (02) : 619 - 623
  • [36] Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo(1,5-a)pyrimidine Inhibitors Using a Focused Library and Structure-Based Optimization Approach
    Kosugi, Tomomi
    Mitchell, Dale R.
    Fujino, Aiko
    Imai, Minoru
    Kambe, Mika
    Kobayashi, Shinji
    Makino, Hiroaki
    Matsueda, Yohei
    Oue, Yasuhiro
    Komatsu, Kanji
    Imaizumi, Keiichiro
    Sakai, Yuri
    Sugiura, Satoshi
    Takenouchi, Osami
    Unoki, Gen
    Yamakoshi, Yuko
    Cunliffe, Vicky
    Frearson, Julie
    Gordon, Richard
    Harris, C. John
    Kalloo-Hosein, Heidi
    Le, Joelle
    Patel, Gita
    Simpson, Donald J.
    Sherborne, Brad
    Thomas, Peter S.
    Suzuki, Naotaka
    Takimoto-Kamimura, Midori
    Kataoka, Ken-ichiro
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (15) : 6700 - 6715
  • [37] Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidine Inhibitors Using a Focused Library and Structure-Based Optimization Approach (vol 55, pg 6700, 2012)
    Kosugi, Tomomi
    Mitchell, Dale R.
    Fujino, Aiko
    Imai, Minoru
    Kambe, Mika
    Kobayashi, Shinji
    Makino, Hiroaki
    Matsueda, Yohei
    Oue, Yasuhiro
    Komatsu, Kanji
    Imaizumi, Keiichiro
    Sakai, Yuri
    Sugiura, Satoshi
    Takenouchi, Osami
    Unoki, Gen
    Yamakoshi, Yuko
    Cunliffe, Vicky
    Frearson, Julie
    Gordon, Richard
    Harris, C. John
    Kalloo-Hosein, Heidi
    Le, Joelle
    Patel, Gita
    Simpson, Donald J.
    Sherborne, Brad
    Thomas, Peter S.
    Suzuki, Naotaka
    Takimoto-Kamimura, Midori
    Kataoka, Ken-ichiro
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 10312 - 10313
  • [38] The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
    Goldberg, Frederick W.
    Finlay, M. Raymond, V
    Ting, Attilla K. T.
    Beattie, David
    Lamont, Gillian M.
    Fallan, Charlene
    Wrigley, Gail L.
    Schimpl, Marianne
    Howard, Martin R.
    Williamson, Beth
    Vazquez-Chantada, Mercedes
    Barratt, Derek G.
    Davies, Barry R.
    Cadogan, Elaine B.
    Ramos-Montoya, Antonio
    Dean, Emma
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (07) : 3461 - 3471
  • [39] Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-Containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo [3,4-d]pyrimidine-6-carboxamide
    Zehnder, Luke
    Bennett, Michael
    Meng, Jerry
    Huang, Buwen
    Ninkovic, Sacha
    Wang, Fen
    Braganza, John
    Tatlock, John
    Jewell, Tanya
    Zhou, Joe Zhongxiang
    Burke, Ben
    Wang, Jeff
    Maegley, Karen
    Mehta, Pramod P.
    Yin, Min-Jean
    Gajiwala, Ketan S.
    Hickey, Michael J.
    Yamazaki, Shinji
    Smith, Evan
    Kang, Ping
    Sistla, Anand
    Dovalsantos, Elena
    Gehring, Michael R.
    Kania, Robert
    Wythes, Martin
    Kung, Pei-Pei
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (09) : 3368 - 3385